The losers, then, might be the other side of that see-saw, the companies that have invested most heavily in the generics: Novartis, Teva Pharmaceutical Industries, and Ranbaxy Laboratories.

FORBES: Supreme Court Helps Big Pharma Stay Fat And Happy In Sorrell Ruling

Large pharmaceutical companies have a vested interest in portraying international generics as unsafe.

FORBES: Magazine Article

Its Sandoz generics subsidiary produces generic drugs as well as active pharmaceutical ingredients.

FORBES: Magazine Article